59
Participants
Start Date
May 30, 2017
Primary Completion Date
July 12, 2018
Study Completion Date
November 14, 2018
Spesolimab (low dose)
12 weeks treatment
Placebo
12 weeks treatment
Spesolimab (high dose)
12 weeks treatment
Bispebjerg og Frederiksberg Hospital, København NV
Gentofte Hospital, Hellerup
Aarhus University Hospital, Skejby, Aarhus
Charité - Universitätsmedizin Berlin, Berlin
TFS Trial Form Support GmbH, Hamburg
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel
Hospital Universitario Infanta Leonor, Madrid
Hospital Ramón y Cajal, Madrid
Universitätsklinikum Frankfurt, Frankfurt am Main
Universitätsklinikum Heidelberg, Heidelberg
Dr. Irina Turchin PC Inc., Fredericton
York Dermatology Clinic and Research Centre, Richmond Hill
Innovaderm Research Inc., Montreal
Ospedale San Giovanni di Dio, Cagliari
Pol. Universitario Tor Vergata, Roma
Hospital Santa Creu i Sant Pau, Barcelona
Sahlgrenska US, Göteborg, Gothenburg
Karolinska Univ. sjukhuset, Stockholm
Lead Sponsor
Boehringer Ingelheim
INDUSTRY